Citarinostat (ACY-241; ACY241; HDAC-IN-2) is a novel, potent, orally bioavailable and selective inhibitor of HDAC6 (histone deacetylase) with anticancer activity.

ACY-775, a novel pyrimidine hydroxyl amide small molecule, is a brain bioavailable, highly potent and isoform-selective inhibitor of HDAC6 with IC50 of 7.5 nM.

Givinostat (formerly known as ITF-2357; Gavinostat) is a potent and orally bioactive inhibitor of both class I and class II histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and anticancer activities.

AES-350 is a novel,potent and selective HDAC6 inhibitor.

SW-100 (SW100), a tetrahydroquinoline-based compound, is a novel, potent, brain penetrant and selective histone deacetylase 6 (HDAC6) inhibitor (IC50 = 2.3 nM) with neuroprotective effects.

FT895 (FT-895; FT 895 ) is a novel and potent HDAC11 (histone deacetylase) inhibitor (IC50 = 3 nM).

Givinostat (ITF-2357 hydrochloride) is a potent and orally bioactive HDAC inhibitor with potential anti-inflammatory, anti-angiogenic, and anticancer activities.

Crebinostat is a novel and potent HDAC (histone deacetylase) inhibitor with anticancer and neuroprotective effects.

Chidamide (CS-055, Tucidinostat, HBI-8000; trade name: Epidaza), is a potent and orally bioavailable benzamide-type histone deacetylase (HDAC) inhibitor with IC50s of 95, 160, 67 and 78 nM for HDAC1, HDAC2, HDAC3 and HDAC10, respectively.

Resminostat HCl (formerly known as RAS-2410; RAS2410 and 4SC-201), the hydrochloride salt of Resminostat, is a potent inhibitor of HDAC (histone deacetylase) classes I and II (including HDAC1/3/6) with anticancer activity.